Evkeeza (evinacumab-dgnb) — Coverage Criteria for Homozygous Familial Hypercholesterolemia (HoFH)
Customize your policy alerts
Sign up for CareSource Policy Arkansas PASSE alerts
Get alerted when Policy Arkansas PASSE changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior-authorization medical benefit coverage of Evkeeza (evinacumab-dgnb) for members with homozygous familial hypercholesterolemia (HoFH) in Arkansas PASSE. It describes initial and reauthorization clinical criteria, required documentation, dosing, and coverage stance.
Changed LDL threshold for diagnostic consideration to >400 mg/dL and specified at least 15% LDL reduction for reauthorization.
Updated age limit and J-code information in prior revisions.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.